Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart scan surprise: notifying patients boosts statin use

NCT ID NCT05588895

Knowledge-focused Sponsor: Stanford University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether notifying patients and their doctors about calcium found in the heart arteries on a routine chest CT scan would lead to more people starting statin medications. Researchers enrolled 202 adults who had this incidental finding and randomly assigned them to receive a notification or usual care. The main goal was to see if the notification increased new statin prescriptions within six months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
notification of coronary artery calcification findings
What this could lead to
If successful, this approach could help more people start cholesterol-lowering medication early, potentially reducing heart attacks and strokes.
What could go wrong
This is a small, completed study focused on changing prescription rates, not on actual heart outcomes. The effect may vary by clinic and patient population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

202 people

The number who actually took part.

Started

Jan 2024

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 84 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 and above and \<85 * Non-gated chest CT with CAC * An encounter after July 1, 2021 with a Stanford-affiliated clinician from one of the following clinics: * Stanford Internal Medicine (includes University affiliated clinics) * Stanford Family Medicine (includes University affiliated clinics) * Non-EP cardiologist Exclusion Criteria: * Advanced or poor-prognostic cancer * No active primary care or cardiology care at Stanford Health Care * Primary language other than English, Spanish, Vietnamese, Cantonese, or Mandarin * Baseline statin or non-statin lipid lowering therapy * Allergy to statin medication or identification of statin-associated muscle symptom

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery calcification are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary atherosclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery calcification

Contacts and locations

Locations

  • Stanford University

    Stanford, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.